Header Logo

Connection

CHRISTIE BALLANTYNE to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Diabetes Mellitus, Type 2.
CHRISTIE BALLANTYNE
Connection Strength
3.524
Diabetes Mellitus, Type 2
  1. Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
    View in: PubMed
    Score: 0.433
  2. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.253
  3. Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. Circulation. 2017 02 21; 135(8):720-723.
    View in: PubMed
    Score: 0.253
  4. From Trials to Practice: Implementing a Clinical Intervention in Community Settings. J Prim Care Community Health. 2025 Jan-Dec; 16:21501319251339190.
    View in: PubMed
    Score: 0.112
  5. A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure. ESC Heart Fail. 2024 Apr; 11(2):1086-1096.
    View in: PubMed
    Score: 0.102
  6. Implementation and Evaluation of a mHealth-Based Community Health Worker Feedback Loop for Hispanics with and at Risk for Diabetes. J Gen Intern Med. 2024 Feb; 39(2):229-238.
    View in: PubMed
    Score: 0.100
  7. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One. 2023; 18(6):e0285259.
    View in: PubMed
    Score: 0.098
  8. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.097
  9. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
    View in: PubMed
    Score: 0.096
  10. Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up. J Gen Intern Med. 2022 09; 37(12):3062-3069.
    View in: PubMed
    Score: 0.089
  11. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.089
  12. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.088
  13. Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Res Care. 2021 08; 9(1).
    View in: PubMed
    Score: 0.086
  14. Biomarker-Based Risk Prediction of Incident Heart?Failure in Pre-Diabetes and?Diabetes. JACC Heart Fail. 2021 03; 9(3):215-223.
    View in: PubMed
    Score: 0.083
  15. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.078
  16. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.070
  17. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017 01 03; 127(1):43-54.
    View in: PubMed
    Score: 0.063
  18. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.062
  19. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet. 2016 Feb; 9(1):71-8.
    View in: PubMed
    Score: 0.058
  20. Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. Diabetes Care. 2015 Aug; 38(8):1544-50.
    View in: PubMed
    Score: 0.056
  21. A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. Physiol Genomics. 2015 Jun; 47(6):215-24.
    View in: PubMed
    Score: 0.055
  22. Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1. J Acad Nutr Diet. 2014 Nov; 114(11):1800-10.e2.
    View in: PubMed
    Score: 0.053
  23. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
    View in: PubMed
    Score: 0.049
  24. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 09; 12:100.
    View in: PubMed
    Score: 0.049
  25. Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. J Am Soc Echocardiogr. 2013 Aug; 26(8):901-909.e1.
    View in: PubMed
    Score: 0.049
  26. Retinol binding protein 4 and incident diabetes--the Atherosclerosis Risk in Communities Study (ARIC Study). Rev Bras Epidemiol. 2013 Jun; 16(2):388-97.
    View in: PubMed
    Score: 0.049
  27. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013 May; 21(5):944-50.
    View in: PubMed
    Score: 0.049
  28. Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. PLoS One. 2013; 8(1):e55113.
    View in: PubMed
    Score: 0.048
  29. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS One. 2012; 7(12):e51237.
    View in: PubMed
    Score: 0.047
  30. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012; 8(3):e1002607.
    View in: PubMed
    Score: 0.045
  31. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.042
  32. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. Int J Epidemiol. 2010 Dec; 39(6):1647-55.
    View in: PubMed
    Score: 0.040
  33. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab. 2010 Nov; 95(11):5097-104.
    View in: PubMed
    Score: 0.040
  34. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Nov; 33(11):2297-303.
    View in: PubMed
    Score: 0.040
  35. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
    View in: PubMed
    Score: 0.038
  36. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Jan; 33(1):197-9.
    View in: PubMed
    Score: 0.038
  37. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities study. Diabetes. 2009 Jan; 58(1):285-9.
    View in: PubMed
    Score: 0.035
  38. Prevalence of metabolic syndrome and associated risk factors in Asian Indians. J Immigr Minor Health. 2008 Aug; 10(4):313-23.
    View in: PubMed
    Score: 0.035
  39. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2007 May 01; 165(9):1047-54.
    View in: PubMed
    Score: 0.032
  40. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007 Jan; 50(1):36-42.
    View in: PubMed
    Score: 0.031
  41. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug; 193(2):283-91.
    View in: PubMed
    Score: 0.031
  42. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006 Sep; 49(9):2086-96.
    View in: PubMed
    Score: 0.030
  43. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004 Sep; 53(9):2473-8.
    View in: PubMed
    Score: 0.027
  44. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
    View in: PubMed
    Score: 0.026
  45. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2004 Jan; 27(1):77-82.
    View in: PubMed
    Score: 0.025
  46. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003 Jul; 52(7):1799-805.
    View in: PubMed
    Score: 0.025
  47. Rare coding variants in 35 genes associate with circulating lipid levels-A multi-ancestry analysis of 170,000 exomes. Am J Hum Genet. 2022 01 06; 109(1):81-96.
    View in: PubMed
    Score: 0.022
  48. Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. Nat Commun. 2021 03 26; 12(1):1927.
    View in: PubMed
    Score: 0.021
  49. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.019
  50. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.019
  51. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.017
  52. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017 Dec; 49(12):1758-1766.
    View in: PubMed
    Score: 0.017
  53. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005 Feb; 28(2):385-90.
    View in: PubMed
    Score: 0.007
  54. Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2003 May; 26(5):1338-43.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.